Royalty Pharma Announces Launch of Senior Notes Offering
August 19 2020 - 9:00AM
Royalty Pharma plc announced today that it intends to offer,
subject to market and other conditions, senior unsecured notes in
multiple tranches (the “Notes”) in a private offering exempt from
registration in accordance with Rule 144A and Regulation S under
the Securities Act of 1933, as amended (the “Securities Act”). The
Notes will be guaranteed on a senior unsecured basis by Royalty
Pharma Holdings Ltd.
Royalty Pharma intends to use the net proceeds
from the Notes, together with available cash on hand, to repay its
existing Term Loan A and Term Loan B facilities and to pay fees and
expenses incurred in connection with the offering, with any
remainder to be used for general corporate purposes.
The Notes are being offered only to persons
reasonably believed to be qualified institutional buyers in
reliance upon Rule 144A under the Securities Act and, outside the
United States, only to non-U.S. persons pursuant to Regulation S
under the Securities Act. The Notes have not been registered under
the Securities Act or any state securities laws and may not be
offered or sold in the United States absent an effective
registration statement or an applicable exemption from registration
requirements under the Securities Act or any state securities
laws.
This press release does not constitute an offer
to sell or a solicitation of an offer to buy any securities, nor
does it constitute an offer, solicitation or sale in any
jurisdiction in which such offer, solicitation or sale is
unlawful.
About Royalty PharmaFounded in
1996, Royalty Pharma is the largest buyer of biopharmaceutical
royalties and a leading funder of innovation across the
biopharmaceutical industry, collaborating with innovators from
academic institutions, research hospitals and not-for-profits
through small and mid-cap biotechnology companies to leading global
pharmaceutical companies. Royalty Pharma has assembled a portfolio
of royalties which entitles it to payments based directly on the
top-line sales of many of the industry’s leading therapies. Royalty
Pharma funds innovation in the biopharmaceutical industry both
directly and indirectly - directly when it partners with companies
to co-fund late-stage clinical trials and new product launches in
exchange for future royalties, and indirectly when it acquires
existing royalties from the original innovators. Royalty Pharma’s
current portfolio includes royalties on more than 45 commercial
products, including AbbVie and J&J’s Imbruvica, Astellas and
Pfizer’s Xtandi, Biogen’s Tysabri, Gilead’s HIV franchise, Merck’s
Januvia, Novartis’ Promacta, and Vertex’s Kalydeco, Symdeko and
Trikafta, and four development-stage product candidates.
Forward-Looking StatementsThis
press release contains statements that constitute “forward-looking
statements” as that term is defined in the United States Private
Securities Litigation Reform Act of 1995, including statements that
express the company’s opinions, expectations, beliefs, plans,
objectives, assumptions or projections regarding future events or
future results, in contrast with statements that reflect historical
facts. Examples include discussion of our strategies, financing
plans, growth opportunities and market growth. In some cases, you
can identify such forward-looking statements by terminology such as
“anticipate,” “intend,” “believe,” “estimate,” “plan,” “seek,”
“project,” “expect,” “may,” “will,” “would,” “could” or “should,”
the negative of these terms or similar expressions. Forward-looking
statements are based on management’s current beliefs and
assumptions and on information currently available to the company.
However, these forward-looking statements are not a guarantee of
our performance, and you should not place undue reliance on such
statements. Forward-looking statements are subject to many risks,
uncertainties and other variable circumstances, and other factors.
Such risks and uncertainties may cause the statements to be
inaccurate and readers are cautioned not to place undue reliance on
such statements. Many of these risks are outside of the company’s
control and could cause its actual results to differ materially
from those it thought would occur. The forward-looking statements
included in this document are made only as of the date hereof. The
company does not undertake, and specifically declines, any
obligation to update any such statements or to publicly announce
the results of any revisions to any such statements to reflect
future events or developments, except as required by law.
Royalty Pharma Investor Relations and
Communications:+1 (212) 883-0200ir@royaltypharma.com
Royalty Pharma (NASDAQ:RPRX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Royalty Pharma (NASDAQ:RPRX)
Historical Stock Chart
From Sep 2023 to Sep 2024